Literature DB >> 25310145

Antiretroviral procurement and supply chain management.

David J Ripin1, David Jamieson, Amy Meyers, Umesh Warty, Mary Dain, Cyril Khamsi.   

Abstract

Procurement, the country-level process of ordering antiretrovirals (ARVs), and supply chain management, the mechanism by which they are delivered to health-care facilities, are critical processes required to move ARVs from manufacturers to patients. To provide a glimpse into the ARV procurement and supply chain, the following pages provide an overview of the primary stakeholders, principal operating models, and policies and regulations involved in ARV procurement. Also presented are key challenges that need to be addressed to ensure that the supply chain is not a barrier to the goal of universal coverage. This article will cover the steps necessary to order and distribute ARVs, including different models of delivery, key stakeholders involved, strategic considerations that vary depending on context and policies affecting them. The single drug examples given illustrate the complications inherent in fragmented supply and demand-driven models of procurement and supply chain management, and suggest tools for navigating these hurdles that will ultimately result in more secure and reliable ARV provision. Understanding the dynamics of ARV supply chain is important for the global health community, both to ensure full and efficient treatment of persons living with HIV as well as to inform the supply chain decisions for other public health products.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25310145     DOI: 10.3851/IMP2903

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  9 in total

1.  Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community.

Authors:  Yao Liu; Omar Galárraga
Journal:  Health Policy Plan       Date:  2017-03-01       Impact factor: 3.344

Review 2.  A systematic review of pooled procurement of medicines and vaccines: identifying elements of success.

Authors:  Koray Parmaksiz; Elizabeth Pisani; Roland Bal; Maarten Olivier Kok
Journal:  Global Health       Date:  2022-06-11       Impact factor: 10.401

Review 3.  Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Authors:  Urvi M Parikh; John W Mellors
Journal:  Curr Opin HIV AIDS       Date:  2016-01       Impact factor: 4.283

4.  Antimicrobial Resistance and Substandard and Falsified Medicines: The Case of HIV/AIDS.

Authors:  Amitabh B Suthar; William Coggin; Elliot Raizes
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

5.  The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.

Authors:  Arin Dutta; Catherine Barker; Ashley Kallarakal
Journal:  PLoS Med       Date:  2015-11-24       Impact factor: 11.069

Review 6.  The Need for Pediatric Formulations to Treat Children with HIV.

Authors:  Adrienne F Schlatter; Andrew R Deathe; Rachel C Vreeman
Journal:  AIDS Res Treat       Date:  2016-06-16

7.  Generic substitution of antiretrovirals: patients' and health care providers' opinions.

Authors:  Jennifer A Kieran; Eimear O'Reilly; Siobhan O'Dea; Colm Bergin; Aisling O'Leary
Journal:  Int J STD AIDS       Date:  2017-03-02       Impact factor: 1.359

8.  Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?

Authors:  Eduard J Beck; Sundhiya Mandalia; Boniface DongmoNguimfack; Eloan Pinheiro; Ellen 't Hoen; Pascale Boulet; John Stover; Aashta Gupta; Sandeep Juneja; Vincent Habiyambere; Peter Ghys; Cesar Nunez
Journal:  Glob Health Action       Date:  2019       Impact factor: 2.640

Review 9.  Transformation of the Tanzania medical store department through global fund support: an impact assessment study.

Authors:  Patrick Githendu; Linden Morrison; Rosemary Silaa; Sai Pothapregada; Sarah Asiimwe; Rafiu Idris; Tatjana Peterson; Emma Davidson; Abaleng Lesego; Neema Mwale; Sako Mayrick Mwakalobo; Laurean Rugambwa Bwanakunu; Tom Achoki
Journal:  BMJ Open       Date:  2020-11-06       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.